Faes Farma - Public Comps and Valuation Multiples

Faes Farma Overview

About Faes Farma

Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Founded

1933

HQ

Employees

1.2K+

Website

faes.es

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
Health & Beauty
BioTech

Financials

LTM Revenue $670M

LTM EBITDA $144M

EV

$1.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Faes Farma Financials

As of November 2025, Faes Farma reported last 12-month revenue of $670M and EBITDA of $144M.

In the same period, Faes Farma achieved $92.7M in LTM net income.

See Faes Farma valuation multiples based on analyst estimates

Faes Farma P&L

In the most recent fiscal year, Faes Farma reported revenue of $574M and EBITDA of $149M.

Faes Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Faes Farma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$670M	XXX	$574M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$380M	XXX	XXX	XXX
Gross Margin	n/a	XXX	66%	XXX	XXX	XXX
EBITDA	$144M	XXX	$149M	XXX	XXX	XXX
EBITDA Margin	22%	XXX	26%	XXX	XXX	XXX
EBIT	$111M	XXX	$128M	XXX	XXX	XXX
EBIT Margin	17%	XXX	22%	XXX	XXX	XXX
Net Profit	$92.7M	XXX	$129M	XXX	XXX	XXX
Net Margin	14%	XXX	23%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Faes Farma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $670M. EBITDA for the last twelve months was $144M. In the most recent fiscal year, Faes Farma achieved $574M in revenue and $149M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$670M	Analyst estimates available to subscribers	$574M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$380M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	66.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$144M	Analyst estimates available to subscribers	$149M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	21.5% EBITDA margin	Analyst estimates available to subscribers	26.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$111M	Analyst estimates available to subscribers	$128M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.6% EBIT margin	Analyst estimates available to subscribers	22.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$92.7M	Analyst estimates available to subscribers	$129M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	13.8% net profit margin	Analyst estimates available to subscribers	22.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Faes Farma

This financial data table provides comprehensive performance metrics for Faes Farma, a company based in Spain. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Faes Farma generated $670M in revenue over the last twelve months.
The company achieved $144M in EBITDA over the last twelve months.
Net income over the last twelve months reached $92.7M.

Fiscal Year Performance

In the most recent fiscal year, Faes Farma reported $574M in total revenue.
Fiscal year EBITDA was $149M.
The company maintained a gross profit margin of 66.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.0%.
Net profit margin reached 22.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Faes Farma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Faes Farma Stock Performance

Faes Farma has current market cap of EUR 1.5B (or $1.7B), and EV of EUR 1.5B (or $1.7B).

Market Cap Evolution

Faes Farma Stock Data

As of December 4, 2025, Faes Farma's stock price is EUR 5 (or $6).

See Faes Farma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.7B	$1.7B	XXX	XXX	XXX	XXX	$0.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Faes Farma Valuation Multiples

Faes Farma's trades at 3.0x EV/Revenue multiple, and 11.5x EV/EBITDA.

See valuation multiples for Faes Farma and 15K+ public comps

Faes Farma Financial Valuation Multiples

As of December 4, 2025, Faes Farma has market cap of $1.7B and EV of $1.7B.

Equity research analysts estimate Faes Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Faes Farma has a P/E ratio of 18.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV/Revenue	2.6x	XXX	3.0x	XXX	XXX	XXX
EV/EBITDA	11.9x	XXX	11.5x	XXX	XXX	XXX
EV/EBIT	15.5x	XXX	13.4x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	18.7x	XXX	13.4x	XXX	XXX	XXX
EV/FCF	-13.3x	XXX	19.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Faes Farma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Faes Farma Margins & Growth Rates

Faes Farma's last 12 month revenue growth is 22%

Faes Farma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Faes Farma's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Faes Farma's rule of X is 78% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Faes Farma and other 15K+ public comps

Faes Farma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	22%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	22%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	26%	XXX	0%	XXX	XXX	XXX
Rule of 40	50%	XXX	48%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	78%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial